NGeneBio Co., Ltd.
Financials
Valuation Metrics
NGeneBio Co., Ltd.'s Market Cap is ₩156B. At end of 2025 it was ₩320B. Ranked #2383 of 2,436 in KR market (top 98%), #1603 of 1,649 on KOSDAQ (top 97%), #232 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 15.61B KRW | KR#2,383/2,436 Sec#232/234 |
| Revenue | 31.16B KRW | KR#2,013/2,436 Sec#138/234 |
| Net Income | -7.93B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 71.69B KRW | KR#1,974/2,436 Sec#166/234 |
| Net Assets | 22.12B KRW | KR#2,254/2,436 Sec#211/234 |
| Employees | 96 | KR#1,657/2,436 Sec#128/234 |
| Value | ||
| P/B | 0.71x | KR#1,121/2,436 Sec#60/234 |
| P/S | 0.50x | KR#901/2,436 Sec#37/234 |
| FCF Yield | -54.70% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -35.87% | KR#2,210/2,436 Sec#183/234 |
| ROA | -11.07% | KR#2,103/2,436 Sec#165/234 |
| Op. Margin | -22.41% | KR#2,142/2,436 Sec#144/234 |
| Revenue Growth | 487.11% | KR#20/2,436 Sec#4/234 |
| Financial Health | ||
| Debt Ratio | 324.10% | KR#2,180/2,436 Sec#223/234 |
| Total Debt | 32.25B KRW | KR#1,163/2,436 Sec#89/234 |
| FCF | -8.54B KRW | KR#1,663/2,436 Sec#140/234 |
| Cash | 2.97B KRW | KR#2,159/2,436 Sec#204/234 |
| Current Ratio | 0.48x | KR#2,263/2,436 Sec#217/234 |
| Performance | ||
| 1Y Return | -60.00% | KR#2,250/2,436 Sec#214/234 |
| 1M Return | -3.37% | KR#1,359/2,436 Sec#125/234 |
| From 52W High | -74.25% | KR#2,245/2,436 Sec#205/234 |
| 1Y MDD | -80.17% | KR#2,298/2,436 Sec#213/234 |
| Trading | ||
| Volume | 61,542 shares | KR#1,170/2,436 Sec#113/234 |
| Foreign Own. | 1.76% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -873 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,525 KRW | KR#1,900/2,436 Sec#151/234 |
Company Info
Established in 2015, NGENBIO is a specialized NGS-based precision diagnostics company. It was listed on the KOSDAQ market in 2020 and expanded its pharmaceutical distribution business through an acquisition in 2025. The company provides gene extraction panels and data analysis software for conditions like breast cancer and blood cancer, and operates toxicology and molecular diagnostics services. NGENBIO supplies products to over 25 major medical institutions in Korea, expands overseas exports, and is leading the precision medicine market. NGENBIO is headquartered in Guro-gu, Seoul.